Chemical Pathology and Hypertension: Biomarkers, Mechanisms, and Clinical Utility

Role of Clinical Biochemistry in Hypertension

Chemical pathology (clinical biochemistry) identifies underlying causes, assesses target organ damage, guides therapy, and monitors treatment.

Key Biochemical Domains

1. Electrolytes & Volume

  • Sodium, potassium, chloride, bicarbonate – detect hyperaldosteronism, renal tubular acidosis, diuretic effects.
  • Renin, aldosterone, ARR (aldosterone/renin ratio) – screen for primary aldosteronism.

2. Renal Function

  • Creatinine, eGFR, cystatin C – CKD staging (major HTN cause/complication).
  • Urine ACR (albumin-creatinine ratio) – early diabetic/hypertensive nephropathy.

3. Lipid Metabolism

  • LDL-C, HDL-C, triglycerides, non-HDL-C, apoB – cardiovascular risk stratification.
  • Statins indicated for most hypertensive patients with additional risk factors.

4. Glucose & Insulin Resistance

  • Fasting glucose, HbA1c, HOMA-IR – metabolic syndrome, diabetes (HTN amplifier).

5. Inflammatory & Oxidative Markers

  • hs-CRP, IL-6, fibrinogen – vascular inflammation, endothelial dysfunction.

6. Endocrine Workup (Secondary HTN)

  • TSH, free T4 (thyroid); metanephrines (pheochromocytoma); cortisol, dexamethasone suppression (Cushing's); 17-OH progesterone (CAH).

7. Therapeutic Drug Monitoring

  • Levels for drugs with narrow therapeutic index (e.g., cyclosporine, tacrolimus in transplant HTN).
  • Adherence monitoring (urine drug screens for antihypertensives).

8. Genetic Testing (Emerging)

  • Monogenic HTN syndromes (Liddle, Gordon, AME).
  • Polygenic risk scores (research phase).

Clinical Integration

Panels (e.g., "hypertension workup") standardize evaluation. Serial monitoring detects electrolyte shifts, renal decline, metabolic changes—enabling proactive therapy adjustment.

Hypertension - Related Articles